Change of Director's Interest Notice
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information
and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Neurizon Therapeutics Limited
ABN 35 094 006 023
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director Sergio Duchini
Date of last notice 26 March 2026
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Direct or indirect interest Direct & Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Kelbury Pty Ltd
Mr Duchini is a Director of the above
holder which is the registered holder of
the securities
Date of change 14 September 2026
No. of securities held prior to change Indirect
3,607,456 fully paid ordinary shares
Direct
960,000 unlisted options, exercisable at
$0.20 (20 cents) each, expiring 30 June
2032
Class Fully paid ordinary shares
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 01/01/2011
Number acquired Direct
372,960 fully paid ordinary shares
Number disposed -
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$29,960.01
No. of securities held after change Indirect
3,607,456 fully paid ordinary shares
Direct
372,960 fully paid ordinary shares
960,000 unlisted options, exercisable at
$0.20 (20 cents) each, expiring 30 June
2032
Nature of change
Example: on-market trade, off-market trade, exercise of options,
issue of securities under dividend reinvestment plan, participation in
buy-back
On market acquisition.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in
relation to which the interest has changed
N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
N/A
Interest after change N/A
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Part 3 – +Closed period
Were the interests in the securities or contracts
detailed above traded during a +closed period
where prior written clearance was required?
No
If so, was prior written clearance provided to allow
the trade to proceed during this period?
N/A
If prior written clearance was provided, on what
date was this provided?
N/A
Share your feedback
Discover